Ivacaftor/tezacaftor

Drug Profile

Ivacaftor/tezacaftor

Alternative Names: Ivacaftor/VX 661; Tezacaftor/ivacaftor; VX-661/ivacaftor; VX-661/VX-770; VX-770/VX-661

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Cyclopropanes; Fluorobenzenes; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Ion channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cystic fibrosis

Most Recent Events

  • 18 Oct 2016 Phase-III clinical trials in Cystic fibrosis (In children) in USA (PO) in October 2016 (NCT02953314)
  • 15 Aug 2016 Vertex Pharmaceuticals completes enrolment in its phase III trial for Cystic Fibrosis (In adolescents, In adults) in USA, Canada, Denmark, France, Ireland, Italy, Netherlands, Spain, Sweden, Germany, Switzerland and UK
  • 01 Aug 2016 Vertex Pharmaceuticals initiates a phase II trial for Cystic fibrosis (In adolescents, In adults) in Australia (NCT02730208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top